

Tommaso Lupia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4246801/publications.pdf>

Version: 2024-02-01

57
papers

670
citations

759233

12
h-index

610901

24
g-index

57
all docs

57
docs citations

57
times ranked

993
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 novel coronavirus (2019-nCoV) outbreak: A new challenge. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 21, 22-27.	2.2	232
2	Ozone therapy in COVID-19: A narrative review. <i>Virus Research</i> , 2021, 291, 198207.	2.2	44
3	Carbapenem-sparing strategy: carbapenemase, treatment, and stewardship. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 663-673.	3.1	40
4	Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): Role in SARS-CoV-2-related lung injury. <i>Respiratory Physiology and Neurobiology</i> , 2021, 288, 103645.	1.6	23
5	Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?. <i>International Immunopharmacology</i> , 2021, 101, 108200.	3.8	20
6	Microbiome in the setting of burn patients: implications for infections and clinical outcomes. <i>Burns and Trauma</i> , 2020, 8, tkaa033.	4.9	18
7	Presence of Epstein-Barr virus DNA in cerebrospinal fluid is associated with greater HIV RNA and inflammation. <i>Aids</i> , 2020, 34, 373-380.	2.2	17
8	Pulmonary Echinococcosis or Lung Hydatidosis: A Narrative Review. <i>Surgical Infections</i> , 2021, 22, 485-495.	1.4	17
9	Ceftobiprole Perspective: Current and Potential Future Indications. <i>Antibiotics</i> , 2021, 10, 170.	3.7	17
10	Risk Factors for Mortality in COVID-19 Hospitalized Patients in Piedmont, Italy: Results from the Multicenter, Regional, CORACLE Registry. <i>Journal of Clinical Medicine</i> , 2021, 10, 1951.	2.4	17
11	Infection Control in the Era of COVID-19: A Narrative Review. <i>Antibiotics</i> , 2021, 10, 1244.	3.7	15
12	New cephalosporins for the treatment of pneumonia in internal medicine wards. <i>Journal of Thoracic Disease</i> , 2020, 12, 3747-3763.	1.4	14
13	Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β -Lactam/ β -Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians. <i>Pharmaceuticals</i> , 2022, 15, 463.	3.8	13
14	Anaerobic bloodstream infections in Italy (ITANAEROBY): A 5-year retrospective nationwide survey. <i>Anaerobe</i> , 2022, 75, 102583.	2.1	13
15	Epidemiology, prevalence and risk factors for infections in burn patients: results from a regional burn centre's analysis. <i>Journal of Chemotherapy</i> , 2021, 33, 62-66.	1.5	11
16	Novel Cephalosporins in Septic Subjects and Severe Infections: Present Findings and Future Perspective. <i>Frontiers in Medicine</i> , 2021, 8, 617378.	2.6	11
17	Non-fermentative gram-negative bloodstream infection in northern Italy: a multicenter cohort study. <i>BMC Infectious Diseases</i> , 2021, 21, 806.	2.9	11
18	Putative invasive pulmonary aspergillosis within medical wards and intensive care units: a 4-year retrospective, observational, single-centre study. <i>Internal and Emergency Medicine</i> , 2021, 16, 1619-1627.	2.0	10

#	ARTICLE	IF	CITATIONS
19	Exogenous Fungal Endophthalmitis: Clues to Aspergillus Aetiology with a Pharmacological Perspective. <i>Microorganisms</i> , 2021, 9, 74.	3.6	9
20	Giardiasis reactivation during severe SARS-CoV-2 infection. <i>Parasitology International</i> , 2021, 80, 102241.	1.3	8
21	Vaccine development and technology for SARS-CoV-2: Current insight. <i>Journal of Medical Virology</i> , 2022, 94, 878-896.	5.0	8
22	Carbapenemase-Producing <i>Klebsiella pneumoniae</i> Colonization and Infection in Solid Organ Transplant Recipients: A Single-Center, Retrospective Study. <i>Microorganisms</i> , 2021, 9, 2272.	3.6	8
23	Testosterone as a Biomarker of Adverse Clinical Outcomes in SARS-CoV-2 Pneumonia. <i>Biomedicines</i> , 2022, 10, 820.	3.2	8
24	Temocillin: Applications in Antimicrobial Stewardship as a Potential Carbapenem-Sparing Antibiotic. <i>Antibiotics</i> , 2022, 11, 493.	3.7	8
25	Antiviral treatment with pegylated interferon and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: A retrospective analysis. <i>Journal of Medical Virology</i> , 2019, 91, 1329-1334.	5.0	7
26	Risk Factors for Candidemia After Open Heart Surgery: Results From a Multicenter Case-Control Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa233.	0.9	7
27	COVID-19 pneumonia: do not leave the corticosteroids behind!. <i>Future Microbiology</i> , 2021, 16, 317-322.	2.0	7
28	Clinical and microbiological characteristics of bloodstream infections caused by <i>Enterococcus</i> spp. within internal medicine wards: a two-year single-centre experience. <i>Internal and Emergency Medicine</i> , 2022, 17, 1129-1137.	2.0	6
29	Enteropathogenetic nosocomial infections: predisposing clinical characteristics and risk of recurrent infections. <i>Journal of Chemotherapy</i> , 2019, 31, 394-400.	1.5	4
30	Efficacy and safety of interferon-free regimens in patients affected by chronic hepatitis C and psychiatric disorders. <i>Journal of Infection and Chemotherapy</i> , 2020, 26, 18-22.	1.7	4
31	Antiviral treatment selection for SARS-CoV-2 pneumonia. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 985-992.	2.5	4
32	Antibiotic De-escalation Experience in the Setting of Emergency Department: A Retrospective, Observational Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3285.	2.4	4
33	Infective Endocarditis in People Who Inject Drugs: Report from the Italian Registry of Infective Endocarditis. <i>Journal of Clinical Medicine</i> , 2022, 11, 4082.	2.4	4
34	Visceral leishmaniasis in a patient with active HBV/HDV co-infection. <i>Journal of Infection and Public Health</i> , 2020, 13, 306-308.	4.1	3
35	The Management of Hematologic Patients with Bloodstream Infections Due to Multi-Drug Resistant Bacteria: Where Do We Stand? From Antibacterial Prophylaxis to the Treatment of Septic Shock. <i>Hemato</i> , 2020, 1, 60-76.	0.6	3
36	Bacterial and Viral Infections in Liver Transplantation: New Insights from Clinical and Surgical Perspectives. <i>Biomedicines</i> , 2022, 10, 1561.	3.2	3

#	ARTICLE	IF	CITATIONS
37	Retreatment with Sofosbuvir/Velpatasvir in Cirrhotic Patients with Genotype-4 who Failed a Previous Interferon-Free Regimen: A Case Series. <i>Antiviral Therapy</i> , 2018, 23, 543-547.	1.0	2
38	Daptomycin-based aminoglycoside-sparing therapy for streptococcal endocarditis: a retrospective multicenter study. <i>Journal of Chemotherapy</i> , 2021, 33, 435-439.	1.5	2
39	COVID-19: in the uncertainty, do not try this at home. <i>Internal and Emergency Medicine</i> , 2020, 15, 1599-1600.	2.0	2
40	COVID-19: where have the lymphocytes gone?. <i>Internal Medicine Journal</i> , 2020, 50, 1436-1437.	0.8	2
41	Infections in Sjögren syndrome: A retrospective cohort study of 113 patients. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	1.2	2
42	Observed concentrations of amikacin and gentamycin in the setting of burn patients with gram-negative bacterial infections: Preliminary data from a prospective study. <i>Thérapie</i> , 2021, 76, 409-414.	1.0	2
43	Beta Lactams Plus Daptomycin Combination Therapy for Infective Endocarditis: An Italian National Survey (BADAS). <i>Antibiotics</i> , 2022, 11, 56.	3.7	2
44	Disseminated Cryptococcosis Complicating Severe SARS-CoV-2 Infection. <i>BioMed</i> , 2022, 2, 127-132.	1.1	2
45	Real-life use of isavuconazole outside the hematological wards. <i>European Journal of Internal Medicine</i> , 2019, 70, e10-e12.	2.2	1
46	I have got you under my skin. <i>Infection</i> , 2020, 48, 315-316.	4.7	1
47	Antiviral Therapy in Patients With Hepatitis B Virus Treated for Tuberculosis: A Forgotten Issue. <i>Clinical Infectious Diseases</i> , 2020, 71, 1583-1584.	5.8	1
48	Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study. <i>Archives of Virology</i> , 2021, 166, 1125-1131.	2.1	1
49	A tinea immune reconstitution inflammatory syndrome in a HIV-positive patient starting combination antiretroviral treatment. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 695-697.	0.8	1
50	Serology for <i>Borrelia</i> spp. in Northwest Italy: A Climate-Matched 10-Year Trend. <i>Life</i> , 2021, 11, 1310.	2.4	1
51	Good times, bad times: A diary of a physician in the COVID-19 era. <i>European Journal of Internal Medicine</i> , 2020, 77, 132-133.	2.2	0
52	Beware of the dog. <i>European Journal of Internal Medicine</i> , 2020, 74, 102-103.	2.2	0
53	Plasmatic and intracellular concentration of entecavir during treatment of a symptomatic flare in HBV-HDV decompensated cirrhosis. <i>Journal of Infection and Public Health</i> , 2020, 13, 315-316.	4.1	0
54	Personalized stewardship and interdisciplinarity: key elements of COVID-19. <i>Microbes and Infection</i> , 2021, 23, 104781.	1.9	0

#	ARTICLE	IF	CITATIONS
55	Matters of time. Intensive Care Medicine, 2021, 47, 1175-1176.	8.2	0
56	Poppies, Bloom. Journal of Medical Humanities, 2021, 42, 507-510.	0.7	0
57	Live forever. Intensive Care Medicine, 2022, , 1.	8.2	0